Biomarin projects 2022 Voxzogo sales of USD 115m

US-based Biomarin brought its dwarfism drug Voxzogo to the market in 2021, and the company has great expectations for the drug in 2022.

Biomarin's Voxzogo is designed to treat achondroplasia, also known as dwarfism | Photo: Anders Rye Skjoldjensen

US-based biotech firm Biomarin has released its full-year financial report on Wednesday, and in connection with the report came the company’s 2022 sales prognosis for potential cash cow Voxzogo.

Biomarin is projecting that sales of the treatment for achondroplasia, also known as dwarfism, could reach as much as USD 115m in 2022.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs